Christian Thomas Ruff
Brigham and Women's Hospital
2 papers in the Anchorcite directory, published between 2013 and 2018, cited 11,859 times in total.
ORCID profileResearch topics
- Diabetes Treatment and Management · 1 paper
- Chronic Kidney Disease and Diabetes · 1 paper
- Heart Failure Treatment and Management · 1 paper
- Acute Ischemic Stroke Management · 1 paper
- Atrial Fibrillation Management and Outcomes · 1 paper
- Venous Thromboembolism Diagnosis and Management · 1 paper
Frequent co-authors
- Stephen D. Wiviott · 2 papers
- Itamar Raz · 1 paper
- Marc P. Bonaca · 1 paper
- Ofri Mosenzon · 1 paper
- Eri Toda Kato · 1 paper
- Avivit Cahn · 1 paper
- Michael G. Silverman · 1 paper
- Thomas A. Zelniker · 1 paper
Papers
- Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine · 2018 · 6,600 citations
BACKGROUND: The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. METHODS: of body-surface area, new end-stage renal disease, or death from renal or cardiovascular causes)…
- Edoxaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine · 2013 · 5,259 citations
BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known. METHODS: We conducted a randomized, double-blind, double-dummy trial…
Metadata from OpenAlex (CC0).